Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OpGen : Note 2 - Liquidity and management's plans

05/08/2020 | 04:40pm EST

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing transactions, including the following in 2019 and 2020 to date:

· On February 11, 2020, the Company entered into an At the Market Common Offering

   (the "ATM Agreement") with H.C. Wainwright & Co., LLC ("Wainwright"), pursuant
   to which the Company may offer and sell from time to time in an "at the market
   offering," at its option, up to an aggregate of $15.7 million of shares of the
   Company's common stock through Wainwright, as sales agent, (the "2020 ATM
   Offering"). During the three months ended March 31, 2020, the Company sold
   2,814,934 shares of its common stock under the 2020 ATM Offering resulting in
   aggregate net proceeds to the Company of approximately $5.5 million, and gross
   proceeds of $5.8 million.

· On October 28, 2019, the Company closed a public offering (the "October 2019

   Public Offering") of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded
   units at $1.99 per pre-funded unit, raising gross proceeds of approximately
   $9.4 million and net proceeds of approximately $8.3 million. Each unit included
   one share of common stock and one common warrant to purchase one share of
   common stock at an exercise price of $2.00 per share. Each pre-funded unit
   included one pre-funded warrant to purchase one share of common stock for an
   exercise price of $0.01 per share, and one common warrant to purchase one share
   of common stock at an exercise price of $2.00 per share. The common warrants
   are exercisable immediately and have a five-year term from the date of
   issuance. As of March 31, 2020, all 2,109,830 pre-funded warrants issued in the
   October 2019 Public Offering have been exercised. Additionally during the three
   months ended March 31, 2020, 4,071,000 common warrants issued in the October
   2019 Public Offering were exercised for net proceeds of approximately $8.1

· On March 29, 2019, the Company closed a public offering (the "March 2019 Public

Offering") of 450,000 shares of its common stock at a public offering price of

$12.00 per share. The offering raised gross proceeds of $5.4 million and net

proceeds of approximately $4.8 million.

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash will be sufficient to fund operations into the fourth quarter of 2020. This has led management to conclude that substantial doubt about the Company's ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of the fourth quarter of 2020, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Note 3 - Summary of significant accounting policies

Basis of presentation and consolidation

The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the following unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company's latest Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company's financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2019 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but does not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen and its wholly-owned subsidiaries as of March 31, 2020 and excludes the Curetis Business which was acquired on April 1, 2020; all intercompany transactions and balances have been eliminated.


Foreign currency

The Company has subsidiaries located in Copenhagen, Denmark, and Bogota, Colombia, both of which use currencies other than the U.S dollar as their functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive (loss)/income, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive (loss)/income at March 31, 2020 and 2019.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to "$" or "dollar" refer to the United States dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, the estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Financial instruments classified as current assets and liabilities (including cash and cash equivalent, receivables, accounts payable, deferred revenue and short-term notes) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash, cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency ("FDIC") insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At March 31, 2020 and December 31, 2019, the Company has funds totaling $185,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying unaudited condensed consolidated balance sheets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows:

© Edgar Online, source Glimpses

All news about OPGEN, INC.
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
11/16OPGEN : Note 2 - Liquidity and management's plans
11/13OPGEN : Corporate Presentation (PDF)
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
11/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements ..
11/11OPGEN : Reports Third Quarter 2020 Financial Results and Provides Business Updat..
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -24,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,16x
Yield 2020 -
Capitalization 39,5 M 39,5 M -
Capi. / Sales 2020 9,58x
Capi. / Sales 2021 3,53x
Nbr of Employees 39
Free-Float 99,9%
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 1,96 $
Spread / Highest target 188%
Spread / Average Target 172%
Spread / Lowest Target 155%
EPS Revisions
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.73.45%40
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
SEAGEN INC.44.08%29 684